Japan approves first-of-its-kind iPSC stem cell therapies for Parkinson's and heart failure
TL;DR Summary
Japan granted conditional approval for two world-first stem cell therapies—AMCHEPRY for Parkinson's and RiHEART for severe heart failure—using induced pluripotent stem cells to replace or repair damaged tissue, with ongoing data collection and long-term safety monitoring.
Topics:health#heart-failure#induced-pluripotent-stem-cells#japan#parkinsons-disease#regenerative-medicine#world
- Japan gives green light to first-of-their-kind stem cell therapies Medical News Today
- Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells WIRED
- Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease BioInformant
- Yomiuri: Japan Conditionally Approves World's 1st iPS Cell-based Treatment MarketWatch
- World’s First Treatment Made from Reprogrammed Human Cells Approved in Japan Indian Defence Review
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
7 min
vs 7 min read
Condensed
97%
1,395 → 36 words
Want the full story? Read the original article
Read on Medical News Today